Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jun 30, 2011
Mathematician and bioengineer Sarah Nelson, PhD, and pharmacist Marcus Ferrone, PharmD, apply nuclear magnetic resonance imaging and a new chemical compound to assess the aggressiveness of prostate cancer in patients and the success of prostate cancer therapies. Nelson is a faculty member in the Department of Bioengineering and Therapeutic Sciences, UCSF Schools of Pharmacy and Medicine. Ferrone is a faculty member in the Department of Clinical Pharmacy, UCSF School of Pharmacy.